According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
A number of other equities research analysts have also recently issued reports on the stock. Piper Jaffray Cos. reaffirmed an overweight rating and issued a $23.00 target price (down from $32.00) on shares of NantKwest in a report on Wednesday, August 17th. Canaccord Genuity reaffirmed a buy rating and issued a $18.00 target price on shares of NantKwest in a report on Friday, August 19th. Finally, Raymond James Financial Inc. assumed coverage on shares of NantKwest in a report on Thursday, June 2nd. They issued a market perform rating on the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $17.40.
Shares of NantKwest (NASDAQ:NK) traded down 2.69% during trading on Wednesday, reaching $7.61. The company’s stock had a trading volume of 35,044 shares. The company’s 50-day moving average is $8.00 and its 200-day moving average is $7.66. The company’s market capitalization is $626.39 million. NantKwest has a 12 month low of $5.43 and a 12 month high of $19.43.
In other NantKwest news, insider Barry J. Simon sold 32,000 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $7.49, for a total transaction of $239,680.00. Following the transaction, the insider now owns 3,334,906 shares in the company, valued at approximately $24,978,445.94. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 73.06% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in NK. Vanguard Group Inc. raised its stake in shares of NantKwest by 13.9% in the second quarter. Vanguard Group Inc. now owns 1,583,285 shares of the company’s stock worth $9,848,000 after buying an additional 193,338 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of NantKwest during the second quarter worth $110,000. DekaBank Deutsche Girozentrale raised its stake in shares of NantKwest by 38.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 48,400 shares of the company’s stock worth $302,000 after buying an additional 13,500 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of NantKwest during the second quarter worth $228,000. Finally, Swiss National Bank raised its stake in shares of NantKwest by 16.8% in the second quarter. Swiss National Bank now owns 42,450 shares of the company’s stock worth $264,000 after buying an additional 6,100 shares in the last quarter. Hedge funds and other institutional investors own 24.13% of the company’s stock.
NantKwest Company Profile
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.